NLRP3 and Cognitive impairment: The role of the activation of the non-specific immune response pathway in the development of neurodegeneration may be an attractive target for future therapy because post-mortem studies of brain tissue in people with mild cognitive impairment (MCI) showed a significant increase in the number of activated microglial cells (immunophenotype M2) and a significant increase in the activity of the NLRP3-caspase complex 1 [23].